Frenzen P D
Economic Research Service, US Department of Agriculture, 1800 M Street, N.W., Washington, DC 20036-5831, USA.
Neurology. 2008 Jul 1;71(1):21-7. doi: 10.1212/01.wnl.0000316393.54258.d1.
This study estimated the annual economic cost of Guillain-Barré syndrome (GBS) in the United States in 2004, including the direct costs of medical care and the indirect costs due to lost productivity and premature death.
The cost-of-illness method was used to determine the costs of medical care and lost productivity, and a modified value of a statistical life approach was used to determine the cost of premature deaths. Data were obtained from the Nationwide Inpatient Sample, the Medical Expenditure Panel Survey, the Compressed Mortality File, a telephone survey of 180 adult patients with GBS, and other sources.
The estimated annual cost of GBS was $1.7 billion (95% CI, $1.6 to 1.9 billion), including $0.2 billion (14%) in direct medical costs and $1.5 billion (86%) in indirect costs. Most of the medical costs were for community hospital admissions. Most of the indirect costs were due to premature deaths. The mean cost per patient with GBS was $318,966 (95% CI, $278,378 to 359,554).
The economic cost of Guillain-Barré syndrome (GBS) was substantial, and largely due to disability and death. The cost estimate summarizes the lifetime health burden due to GBS in monetary terms, and provides some of the information needed to assess the cost-effectiveness of health measures that affect GBS.
本研究估算了2004年美国吉兰-巴雷综合征（GBS）的年度经济成本，包括医疗护理的直接成本以及因生产力损失和过早死亡导致的间接成本。
采用疾病成本法确定医疗护理成本和生产力损失成本，并使用一种修改后的统计生命价值法确定过早死亡成本。数据来自全国住院患者样本、医疗支出小组调查、压缩死亡率文件、对180名成年GBS患者的电话调查以及其他来源。
GBS的年度估计成本为17亿美元（95%CI，16亿至19亿美元），其中直接医疗成本为2亿美元（14%），间接成本为15亿美元（86%）。大部分医疗成本用于社区医院住院治疗。大部分间接成本是由于过早死亡。每位GBS患者的平均成本为318,966美元（95%CI，278,378至359,554美元）。
吉兰-巴雷综合征（GBS）的经济成本巨大，主要归因于残疾和死亡。成本估算以货币形式总结了GBS导致的终身健康负担，并提供了评估影响GBS的健康措施成本效益所需的一些信息。
